[{"address1": "75 State Street", "address2": "Suite 100", "city": "Boston", "state": "MA", "zip": "02109", "country": "United States", "phone": "617 229 6499", "website": "https://www.finchtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew P. Blischak J.D.", "age": 61, "title": "President, Secretary & CEO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 558807, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James S. Sigler MBA", "age": 63, "title": "Executive Vice President of CMC", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.0, "open": 11.0, "dayLow": 11.0, "dayHigh": 11.0, "regularMarketPreviousClose": 11.0, "regularMarketOpen": 11.0, "regularMarketDayLow": 11.0, "regularMarketDayHigh": 11.0, "beta": 1.335, "forwardPE": -0.53423995, "volume": 100, "regularMarketVolume": 100, "averageVolume": 2468, "averageVolume10days": 440, "averageDailyVolume10Day": 440, "bid": 11.0, "ask": 11.25, "bidSize": 40000, "askSize": 40000, "marketCap": 17663360, "fiftyTwoWeekLow": 0.8, "fiftyTwoWeekHigh": 14.26, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 11.31606, "twoHundredDayAverage": 7.400325, "currency": "USD", "enterpriseValue": 30617392, "floatShares": 896016, "sharesOutstanding": 1605760, "sharesShort": 19195, "sharesShortPriorMonth": 10600, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.012, "heldPercentInsiders": 0.53457, "heldPercentInstitutions": 0.033099998, "shortRatio": 0.19, "shortPercentOfFloat": 0.0276, "impliedSharesOutstanding": 1605760, "bookValue": 8.855, "priceToBook": 1.2422361, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -14167000, "trailingEps": -8.8, "forwardEps": -20.59, "lastSplitFactor": "1:30", "lastSplitDate": 1686528000, "enterpriseToEbitda": -1.57, "52WeekChange": 2.7453184, "SandP52WeekChange": 0.23809385, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "FNCH", "underlyingSymbol": "FNCH", "shortName": "Finch Therapeutics Group, Inc.", "longName": "Finch Therapeutics Group, Inc.", "firstTradeDateEpochUtc": 1616160600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "b8e86349-7dce-3756-a76c-43df24d3f738", "messageBoardId": "finmb_320858778", "gmtOffSetMilliseconds": -18000000, "currentPrice": 11.0, "recommendationKey": "none", "totalCash": 16035000, "totalCashPerShare": 9.986, "ebitda": -19506000, "totalDebt": 28989000, "quickRatio": 3.594, "currentRatio": 3.872, "debtToEquity": 203.875, "returnOnAssets": -0.2189, "returnOnEquity": -0.67280996, "freeCashflow": -15963625, "operatingCashflow": -18055000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-25"}]